Method of gene therapy using dna vectors without selection marker gene
CA 2197075 C · Owner: Roche Diagnostics Gmbh · Inventors: Ruger, Rudiger; Seeber, Stefan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of a circular vector DNA to manufacture a drug to treat mammals or humans by gene therapy, wherein the vector DNA contains a selection marker gene and a DNA sequence that is heterologous for the vector and that causes a modulation, correction or activation of the expression of an endogenous gene or the expression of a gene introduced into the cells of the mammal or human by the vector DNA, is characterized in that the vector nucleic acid (a) is amplified under selection pressure and is split in such a way that said selection marker gene and said heterologous DNA are present on separate DNA fragments, (b) the DNA fragment that contains said heterologous DNA or both fragments …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 31, 1995 and granted December 21, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 31, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 31, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.